Comparing Profusa (PFSA) & Its Competitors

Profusa (NASDAQ:PFSA) is one of 28 publicly-traded companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it contrast to its competitors? We will compare Profusa to similar businesses based on the strength of its valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations and price targets for Profusa and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1	0	0	0	1.00
Profusa Competitors	76	75	156	6	2.29

As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 50.60%. Given Profusa’s competitors stronger consensus rating and higher probable upside, analysts clearly believe Profusa has less favorable growth aspects than its competitors.

Valuation and Earnings

This table compares Profusa and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Profusa	N/A	-$8.71 million	-1.32
Profusa Competitors	$59.54 million	-$32.15 million	3.99

Profusa’s competitors have higher revenue, but lower earnings than Profusa. Profusa is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

9.8% of Profusa shares are owned by institutional investors. Comparatively, 22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by institutional investors. 11.4% of Profusa shares are owned by insiders. Comparatively, 18.1% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Profusa has a beta of -0.14, meaning that its share price is 114% less volatile than the S&P 500. Comparatively, Profusa’s competitors have a beta of 1.76, meaning that their average share price is 76% more volatile than the S&P 500.

Profitability

This table compares Profusa and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-880.32%
Profusa Competitors	-672.41%	-133.75%	-59.01%

Summary

Profusa competitors beat Profusa on 9 of the 12 factors compared.

About Profusa

NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.